Wednesday, February 10, 2010, 3:33am EST - Canadian Markets open in 5 hours and 57 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Hollis-Eden Pharmaceuticals, Inc. (HEPH)

 On Feb 9: 0.5292 USD   0.00 (0.00%)  
MORE ON HEPH
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Hollis-Eden Pharmaceuticals, In (NGM:HEPH) Delayed quote dataEdit
Last Trade: 0.5292 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 0.5292
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: 13.00
Day's Range: N/A - N/A
52wk Range: 0.27 - 0.98
Volume: 0
Avg Vol (3m): 211,276
Market Cap: 15.57M
P/E (ttm): N/A
EPS (ttm): -0.906
Div & Yield: N/A (N/A%)
Hollis-Eden Pharmaceuticals, Inc. (HEPH)
1d  5d  3m  6m  1y  2y  5y  max 
 Add HEPH to Portfolio   Download Data

HEADLINES
• Bioterrorism Is Risky Business
at CNBC (Tue, Dec 8)
• HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Other Events
EDGAR Online (Mon, Nov 16)
• Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Thera
PRNewswire (Mon, Nov 16)
• HOLLIS EDEN PHARMACEUTICALS INC /DE/ Financials
EDGAR Online Financials (Fri, Nov 13)
• Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conferen
PRNewswire (Thu, Nov 12)
• HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Nov 6)
• HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modific
EDGAR Online (Thu, Oct 22)
• HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listin
EDGAR Online (Wed, Sep 16)
• HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Aug 14)
• HOLLIS EDEN PHARMACEUTICALS INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial Stateme
EDGAR Online (Mon, Jun 15)
More Headlines for HEPH...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Hollis-Eden Pharmaceuticals, Inc., a development-stage pharmaceutical company, engages in the development of a proprietary new class of small molecule compounds based on its hormonal signaling technology platform.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices